VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer

Min-Hye Kim1†, Gi-Eun Yang1,2†, Mi-So Jeong1, Jeong-Yeon Mun1, Sang-Yeop Lee3, Jong-Kil Nam4, Yung Hyun Choi5, Tae Nam Kim6* and Sun-Hee Leem1,2*

Abstract

Background: ABL1 is primarily known as a leukemia-related oncogene due to translocation, but about 2.2% of ABL1 mutations have been identified in bladder cancer, and high expression in solid cancer has also been detected.

Methods: Here, we used the NCBI database, UCSC genome browser gateway and Tandem repeat finder program to investigate the structural characterization of the ABL1 breakpoint region and to identify the variable number of tandem repeats (VNTR). To investigate the relationship between ABL1-MS1 and bladder cancer, a case-controlled study was conducted in 207 controls and 197 bladder cancer patients. We also examined the level of transcription of the reporter gene driven by the ABL1 promoter to determine if the VNTR region affects gene expression.

Results: In our study, one VNTR was identified in the breakpoint region, the intron 1 region of ABL1, and was named ABL1-MS1. In the control group, only two common alleles (TR13, TR15) were detected, but an additional two rare alleles (TR14, TR16) were detected in bladder cancer. A statistically significant association was identified between the rare ABL1-MS1 allele and bladder cancer risk: \( P = 0.013 \). Investigating the level of transcription of the reporter gene driven by the ABL1 promoter, VNTR showed inhibition of ABL1 expression in non-cancer cells 293 T, but not in bladder cancer cells. In addition, ABL1-MS1 was accurately passed on to offspring according to Mendelian inheritance through meiosis.

Conclusions: Therefore, the ABL1-MS1 region can affect ABL1 expression of bladder cancer. This study provides that ABL1-MS1 can be used as a DNA fingerprinting marker. In addition, rare allele detection can predict susceptibility to bladder cancer.

Keywords: ABL1, Breakpoint cluster region, VNTR, Polymorphism, Bladder cancer

Background

The Abelson murine leukemia virus oncogene homolog 1 (ABL1) encodes a kinase and is activated by several switch kinases such as receptor tyrosine kinase (RTK) and cyclic AMP (cAMP), and is involved in various cellular processes including cell growth, division, differentiation and migration [1]. ABL1 presents at 9q34.12 on chromosome 9, translocate with the breakpoint cluster region (BCR) gene on chromosome 22 to form the Philadelphia chromosome, the cause of chronic myelogenous leukemia.
leukemia [2]. The BCR region present in ABL1 contains retrotransposon repeats, a DNA sequence that can be rearranged within the genome, and satellite DNA, a short repeat sequence. It is known that the high density of these repeated sequences can lead to disease-causing genomic structural instability [3, 4]. Although high expression occurs mainly in chronic myelogenous leukemia by translocation of ABL1, it has recently been reported that the ABL1 gene may have an effect on the onset of solid cancer. In particular, an association with bladder cancer in the BCR region of ABL1 has also been reported [5–8].

Bladder cancer is largely divided into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) [9]. At the time of bladder cancer diagnosis, about 70% are NMIBC, and 10% of patients have already found metastatic bladder cancer that has spread to other organs. It often occurs in elderly people in their 60s and 70s, and there are three to four times more male patients than females [10]. In addition, smokers are known to have a very high risk of bladder cancer. While non-muscle invasive bladder cancer patients have a 5-year survival rate of 75%, those who have suffered once are very likely to recur [11]. Previous studies have confirmed that over 80% of ABL1 is expressed in MIBC through IHC experiments, and that imatinib, which inhibits the BCR-ABL1 gene from promoting tyrosine kinase action in cancer cell membranes, may be useful in these patients [12]. And it has been reported that about 2.2% of mutations in the ABL1 are found, especially in bladder cancer patients [13]. In addition, the ABL1 region at position 9q34.12 on chromosome 9 has also been reported as a loss of heterozygosity (LOH) marker that may affect the recurrence of bladder cancer [14].

The occurrence of LOH in genomic DNA has been reported in many cases due to the instability of the repeat sequence [15]. Reports of LOH for this region in bladder cancer suspect a repeat sequence region associated with the occurrence of cancer [14]. Although the function of the repeat sequence in the genome has not been identified much, it is known to be related to genome evolution [16], and its association with disease has also been reported [17]. Many retrotransposon repeats and simple sequence length polymorphisms (SSLP) were identified in the BCR region of ABL1, and one VNTR in the ABL1 intron 1 belonging to the BCR region was identified in this study. The VNTR belonging to SSLP can be used as a DNA typing marker. Thus, it can be used as a paternity marker and is also used as a susceptibility marker for diseases such as Huntington's chorea and cancer [18–20]. Although there were reports of structural features in the BCR region of ABL1, VNTR was not reported in previous studies, so this study focused on the association between VNTR in the BCR region and bladder cancer.

First, whether the ABL1-MS1 allele is polymorphic was investigated, and a case–control study was conducted using genomic DNA samples from male controls and male bladder cancer patients. In addition, family genomic DNA samples were used to confirm whether this region could be used as a paternity marker. We also investigated the effect of the ABL1-MS1 allele on gene expression identified in control and bladder cancer patients. The functional potential of ABL1-MS1, according to the results, will be discussed in this paper.

Methods
Analysis of ABL1 genomic structure and primer construction for VNTR
The NCBI database (https://www.ncbi.nlm.nih.gov/gene) and the UCSC genome browser gateway (https://genome.ucsc.edu/cgi-bin/hgGateway) were used to analyze the genome structure of the BCR region in ABL1. The repeat regions were also analyzed using the RepeatMasker (www.repeatmasker.org) program and the Tandem repeat finder program (http://www.tandem.bu.edu/trf/html). For selecting the VNTR region among SSLP, we identified a VNTR with a repeat unit length of 10–100 bp and a program algorithm score of 1000 or more. The primers’ construction for amplifying the selected VNTR region was made using the Primer 3 program (http://www.bioinfo.ut.ee/primer3-0.4.0/) and the Primer-BLAST program (http://www.ncbi.nlm.nih.gov/tools/primer-blast). Primer sequences used in this study are as follows: ABL1-MS1 primers (Forward 5’-GGAATGGAAAGGTGTTGGG-3’ and Reverse 5’-ACCACCTCTCCACCTCCTC-3’).

Preparation of genomic DNA from peripheral blood lymphocytes of controls and bladder cancer patients
Genomic DNAs were extracted from peripheral blood lymphocytes of 207 male controls and 197 male bladder cancer patients to confirm the polymorphism of the ABL1-MS1 region. A total of 207 individuals in the control group with no personal history of cancers or current cancer were recruited and completed an interview. The controls consist of similar proportions of sex and age range to the cases (Table 1). Cases with bladder cancer and controls were recruited from two different hospitals in the same city. The bioethics committees of Dong-A University Hospital, Pusan National University Hospital approved research plan and procedure: [Dong-A University Hospital (#IRB-07-10-7; Busan, Korea), Pusan National University Hospital (#IRB-H-1706-002-007; #IRB-H-1804-002-065; Busan, Korea)]. For PCR (polymerase chain reaction) experiments, genomic DNA was isolated from 400 µL of whole blood, using the Blood and Cell Culture DNA Mini Kit (Qiagen, CA, USA).
PCR analysis of ABL1-MS1

PCR analysis of human DNA samples was performed using the Coregen Taq polymerase (Coregen, Busan, Korea) with 100 ng genomic DNA. Genomic DNA was amplified using primers (forward and reverse) in addition to a standard PCR mixture of 50 mM KCl, 10 mM Tris–HCl (pH 9.0), 3 mM MgCl₂, and 0.2 mM dTTP, dCTP, dGTP and dATP, made up to a final volume of 30 µl. PCR was conducted in a 9700 Thermalcycler (Perkin-Elmer Inc, CA, USA) under the following conditions: 94 °C for 2 min, 30 cycles of 94 °C for 30 s, 68 °C for 20 s, 72 °C for 3 min and a final extension step at 72 °C for 7 min. PCR products were visualized by 2% SeaKem LE agarose gel electrophoresis in TAE buffer at 60 V for 16 h.

Plasmid construction

To generate a luciferase reporter vector having a fragment of the ABL1 5′-promoter region, a fragment was amplified from normal male genomic DNA containing the ABL1 genomic sequence by PCR and inserted into the NheI/HindIII site of the luciferase reporter vector pGL3-Basic (Promega, Madison, WI, USA). To confirm the effect of ABL1-MS1 on ABL1 expression, two common (TR13 and TR15) alleles and two rare alleles (TR14 and TR16) were amplified from genomic DNA derived from control and case and inserted into the HpaI/SalI sites of the p2000 fragment to generate the reporter plasmids p2000 + TR13, p2000 + TR14, p2000 + TR15, and p2000 + TR16 (Fig. 4). All constructs were confirmed by DNA sequencing.

Cell lines and luciferase assays

The following human cell lines were tested for the effect of ABL1-MS1 on ABL1 expression: 293 T (human embryonic kidney cell line obtained from the Korean Cell Line Bank; KCLB, Seoul, Korea) and UM-UC3 (bladder cancer cell line). For the luciferase assay, cells (4 × 10⁵) were seeded in 24-well plates, cultured overnight and transfected with the ABL1 promoter-luciferase plasmids (0.3 µg per well) using the jetPrime transfection reagent (Polyplus-transfection Inc., NY, USA) at a ratio of DNA/jetPrime of 1:3. Analysis of the cells was performed using a dual-luciferase reporter assay system (Promega) 24 h after completion of the transfection procedure. Firefly luciferase activities were normalized to Renilla luciferase activity, and activity was expressed in relative luciferase units to reflect the promoter activity. Triplicate transfections of each construct were tested for each experiment, and the final results were calculated from four independent experiments.

### Table 1 Age distribution of controls and bladder cancer cases

| Age (years) | Controls N (%) | Bladder cancer N (%) | P value |
|-------------|----------------|---------------------|--------|
| 40–49       | 10 (4.8)       | 7 (3.6)             | 0.9974 |
| 50–59       | 40 (19.3)      | 39 (19.8)           |        |
| 60–69       | 91 (44.0)      | 91 (46.2)           |        |
| 70–79       | 56 (27.1)      | 50 (25.4)           |        |
| 80–89       | 10 (4.8)       | 10 (5.1)            |        |
| Total N     | 207            | 197                 |        |
| Average     | 65.2           | 65.7                |        |
| Median      | 66             | 66                  |        |

Phylogenic tree construction

Nucleotide diversities of each repeat unit of the ABL1-MS1 were calculated for each minisatellite. To examine the extent of sequence divergence, the pairwise distance was calculated using a modified Kimura’s two-parameter model with MEGA3 software [21, 22]. We obtained neighbor-joining trees [23] with Kimura’s two-parameter model using Clustal W [24].

Statistical analysis

Regression analysis was used to determine odd ratios (ORs) for the association between alleles of the VNTR region and the risk of bladder cancer incidence among the control group and bladder cancer patient groups. 95% confidence intervals (CIs) for OR were calculated using logarithms of OR and standard error (SE). The difference was considered to be CI 95% significant. The data were examined using R statistical software (https://www.socscistatistics.com/tests/fisher/default2.aspx) with the Fisher exact test [25]. All tests were two-sided, with P<0.05 considered statistically significant.

Results

Genomic analysis of ABL1-breakpoint cluster and identification of VNTR

In order to find out the distribution of repeat sequences for the ABL1 BCR region, which is known to be a very important region for disease development, we investigated through the Repeatmasker (http://www.repeatmasker.org/) and UCSC genome browser gateway database (http://genome.ucsc.edu/cgi-bin/hgGateway?org=human). (Additional file 1: Fig. S1). In the ABL1 BCR region of about 142 kb in length, short interspersed nuclear element (SINE) was present at the highest frequency, and many repetitive sequences such as long interspersed nuclear element (LINE), long terminal repeat (LTR), and simple repeats were identified (Additional file 1: Fig. S1).
**ABL1** consists of 11 exons and 10 introns, approximately 173 kb in length, located on chromosome 9q34.12 (Fig. 1a). Using the Tandem repeat finder program (http://tandem.bu.edu/trf/trf.html), an area within intron 1 that belongs to the BCR area was analyzed, and one VNTR area (algorithm score > 1000) was identified. We named it **ABL1**-MS1 and the repeat unit of this VNTR was 76 bp, and the expected PCR product size was 1194 bp (Fig. 1b). Through analysis of the GenBank database using the BLASTN program, no significant similarity was found between the **ABL1**-MS1 region and the previously identified region. Therefore, **ABL1**-MS1 identified in this study is unique to **ABL1**, and the properties they impart may be directly related to the **ABL1** function.

**Identification of polymorphism of **ABL1**-MS1 and association of rare alleles of **ABL1**-MS1 with bladder cancer**

It is known that the expression of **ABL1** is high in solid cancers including bladder cancer [26–28], and the structural characteristics of **ABL1** are related to the expression [29]. It has also been reported that the LOH of **ABL1** can be used as a diagnostic marker for bladder cancer recurrence [14]. Therefore, we tried to investigate the possibility whether the variant alleles of the VNTR site identified in this study could be used as a predictive diagnostic marker for bladder cancer. To determine whether the variant alleles of **ABL1**-MS1 could affect the susceptibility of bladder cancer, we examined the frequency of the **ABL1**-MS1 allele and its association with bladder cancer.

To confirm the polymorphism of **ABL1**-MS1, a cases-controls study was performed using genomic DNA from 207 cancer-free male controls and 197 male bladder cancer patients (Fig. 2). Table 1 shows the distribution and ratio by age for the control group and the patient group with bladder cancer used in this study. There was no significant difference between groups according to age ($P=0.997$).

Polymorphic alleles in controls were observed in **ABL1**-MS1 with two alleles containing 13- or 15-repeats, 1113 bp and 1265 bp in length (Table 2). In contrast, four alleles were identified in the bladder cancer patient group, including two rare alleles [the number of repeats was 14 (1189 bp) or 16 (1341 bp); the expected frequency for rare alleles was set as < 1%] and two common alleles (the number of repeats was 13 or 15; Table 2). Rare alleles of **ABL1**-MS1 were identified only in bladder cancer, and the most common alleles had 15 repetitions. The heterozygosity of these two groups was 0.345 in the controls.
### Table 2 Comparison of allelic frequency of ABL1-MS1 between controls and bladder cancer

| # Repeat | Controls Frequency | Bladder cancer Frequency | OR (95% CI)   | P value |
|----------|-------------------|--------------------------|----------------|---------|
| 13 (1113 bp) | 92 | 0.222 | 84 | 0.213 | 0.948 (0.668–1.343) | 0.798 |
| 14 (1189 bp) | 0 | 0 | 3 | 0.008 | ns | 0.116 |
| 15 (1265 bp) | 322 | 0.778 | 304 | 0.772 | 0.965 (0.684–1.362) | 0.866 |
| 16 (1341 bp) | 0 | 0 | 3 | 0.008 | ns | 0.116 |

| Alleles | Controls | Bladder cancer | OR (95% CI) | P value |
|---------|-----------|----------------|-------------|---------|
| Common alleles (13, 15) | 414 | 388 | ns | 0.013* |
| Rare alleles (14, 16) | 0 | 6 | ns | 0.013* |

P value, Fisher exact test

*Statistically significant (P < 0.05)
and 0.359 in the patient’s group with bladder cancer, with no significant difference.

When examining the haploid genotype of ABL1-MS1, three patterns were found in the control group: genotype containing two of TR13, two of TR15 or each of TR13 and TR15. In bladder cancer, five different genotypes were identified as indicated in the right panel of Fig. 2a. There were no statistically significant differences in the frequency of each genotype in the two groups (Fig. 2b). The frequency of appearance of common alleles or rare alleles of ABL1-MS1 was compared and analyzed in control and bladder cancer, respectively. The total frequency of rare ABL1-MS1 alleles was 1.5% in cases, compared to 0% in cancer-free controls (Table 2). The incidence of rare alleles in the bladder cancer patient group was statistically significant compared with the control group (P = 0.013; Table 2). In addition, the frequency of incidence of C/R genotypes with rare alleles also showed statistically significant values (P = 0.013) when comparing the bladder cancer group and the control group (Fig. 2b). These results indicate that the rare allele of ABL1-MS1 is associated with the risk of bladder cancer.

The average age at diagnosis of bladder cancer patients is about 65 years old. Based on this age, a group that showed onset at a younger age can be divided into a young group (<65 years), and a group diagnosed at an older age can be divided into an old group (≥65 years). The frequency of rare alleles was higher in younger cases (2.92%) than in older cases (0.46%) (Table 3). In younger patients compared to elderly patients, the correlation between the rare ABL1-MS1 allele and bladder cancer was not statistically significant but showed an increased tendency (6.345, CI 0.73–54.82; P = 0.093) (Table 3). Additionally, in comparing the control and cancer patients by the same age group, the association ratio between bladder cancer and the rare ABL1-MS1 allele in young patients was also not statistically significant (P = 0.061) (Table 3), but the risk tended to increase somewhat.

To examine the meiotic segregation of ABL1-MS1 alleles during meiosis, we selected family groups of two and three generations (four and two families, respectively) (Fig. 3). Genomic DNA was then isolated with peripheral blood lymphocytes from the grandparents, parents and two to three children in each family [30, 31]. Due to the low heterozygosity, two common alleles were detected in ABL1-MS1 region in tested families (data not shown), and the transmission of alleles from parent to child in six families was traced (Fig. 3). The results revealed that ABL1-MS1 is subject to Mendelian inheritance (i.e., children carried one minisatellite allele from each parent), and new ABL1-MS1 alleles were not observed during this analysis.

### Possible function of ABL1-MS1 alleles for the expression of ABL1
To examine the possible role of minisatellites in intron regions, we cloned, sequenced and aligned the four different alleles (TR13, TR14, TR15 and TR16) of ABL1-MS1 (Table 4, Additional file 2: Table S1). The consensus sequence of repeat unit was determined by DNA sequencing of the repeat unit sequence present within the ABL1-MS allele, and 20 types of repeat units with a variation of 1–27% were found (Table 4, Additional file 2: Table S1). The consensus sequence for each repeat unit was determined by DNA sequencing of the repeat unit sequence present within the ABL1-MS allele, and 20 types of repeat units with a variation of 1–27% were found (Table 4, Additional file 2: Table S1). The consensus sequence for each repeat unit in ABL1-MS1 was defined from multiple units within it (Table 4, Additional file 2: Table S1). We next constructed the phylogenetic tree for each minisatellite in ABL1-MS1, as shown in Additional file 1: Fig. S2a. The distance between the repeat units was analyzed through the degree of divergence in the sequence (Additional file 1: Fig. S2a).

Then, these four minisatellites were analyzed using the Transfac software (MATCHTM public version 1.0; http://www.gene-regulation.com/pub/databases.html), which found several putative binding sites for the transcription factor GR-alpha, GR-beta [32], EBF [33], C/EBPheta [34], NF-1 [35], FOXP3 [36], Pax-5 [37, 38], p53 [39], STAT4 [40] and TFII-I [41] in the repeats of ABL1-MS1 (Additional file 1: Fig. S2b). These various transcription factors have been reported to be related to various cancers [42]. Therefore, we speculate whether these transcription factors when associated with ABL1-MS1, which play a role in carcinogenesis by influencing ABL1 activity.

| Age                | Controls | Bladder cancer | OR (95% CI) | P value |
|--------------------|----------|----------------|-------------|---------|
|                    | Common   | Rare           | Common      | Rare    |         |
| Younger (<65)      | 174      | 0              | 171         | 5       | ns      |
| Older (≥65)        | 240      | 0              | 217         | 1       | ns      |
| Reference (older group) | ns       | 6.345 (0.73–54.82; P = 0.093) | OR (95% CI) | P value |

*P value, Fisher exact test

*Statistically significant (P < 0.05)
To investigate whether \textit{ABL1}-MS1 affects transcriptional activity, the 2 kb of \textit{ABL1} promoter region was inserted into the pGL3-Basic Luciferase reporter vector (p2000). Four reporter vectors (p2000 + TR13, p2000 + TR14, p2000 + TR15 and p2000 + TR16) were constructed by inserting TRs with four different lengths into the enhancer region of the \textit{ABL1}-promoter vector (p2000) (Fig. 4a). After transfection into 293 T and UC3 cells using these five types of vectors, luciferase activity was investigated. In 293 T cells, the activity of luciferase was significantly reduced when transfected with \textit{ABL1}-promoter vectors containing TR alleles of \textit{ABL1}-MS1 compared to when transfected with \textit{ABL1}-promoter vector (p2000) (Fig. 4b). These results suggest that the repeat sequence of \textit{ABL1}-MS1 suppresses the expression of \textit{ABL1}. On the other hand, in the bladder cancer cell line UC3, inhibition of the \textit{ABL1} promoter activity by the repeat sequence was not seen (Fig. 4b).

**Discussion**

\textit{ABL1} on chromosome 9 undergoes mutual translocation with the \textit{BCR} gene on chromosome 22 to make the Philadelphia chromosome, which is well known to cause chronic myelogenous leukemia [43–48]. There have been many studies on the breakpoint cluster region in which mutual translocation occurs in the \textit{ABL1}, and it has also been reported that many mutations and repeat sequences exist in the region [2, 4, 49, 50]. Among the repetitive nucleotide sequences found in the human genome, nucleotide sequences such as LINE, SINE, LTR, and SSLP play an important role as a regulator of biological genome evolution and gene expression, and are reported
as genetic causes of various diseases [16–20]. Therefore, in this study, the distribution of repetitive sequences within this BCR region was analyzed and a meaningful VNTR region (ABL1-MS1) was identified in the intron 1 region of ABL1.

In this study, the polymorphism of the ABL1-MS1 region was detected, and each ABL1-MS1 allele was found to be accurately transmitted from parent to the next generation. In a case–control study using genomic DNA from 207 cancer-free controls and 197 bladder cancer patients, rare alleles (TR14, TR16) with a frequency of less than 1% were identified only in bladder cancer. The rare alleles identified only in bladder cancer showed a statistically significant association with cancer risk (P = 0.013). In addition, as a result of comparing the frequency of rare alleles by age based on the age of bladder cancer at 65, there was an increased tendency for association in the younger group (P = 0.061). These results suggest that rare ABL1-MS1 allele may be genetically related to bladder cancer.

In addition, since abnormal expression of ABL1 has been reported in solid cancers including bladder cancer [5–8, 26–29], the effect of this VNTR region on the expression of ABL1 was investigated. First, four TRs (TR13–TR16) identified in this study were sequenced, and analyzed the putative transcription factors using Transfac software. The following transcription factors that appear to be involved in the development and progression of cancer have been identified as being present within the repeat sequence: GR-alpha, GR-beta [32], EBF [33], C/EBPbeta [34], NF1 [35], FOXP3 [36], Pax-5 [37, 38], p53 [39], STAT4 [40] and TFF1-I [41].

Glucocorticoid receptor (GR) is expressed in various isotypes such as GR-alpha and GR-beta, and it is known as a transcription factor involved in the expression of genes involved in cell cycle arrest and apoptosis, and it has been reported that low expression of GR is
related to bladder cancer [32]. Early B-cell factor (EBF) is a DNA-binding transcription factor involved in the differentiation and maturation of various cell lineages. It has been reported that deletion of the EBF gene contributes to leukemia recurrence and, when inactivated, contributes to tumor formation [33]. CCAAT enhancer binding protein beta (C/EBP beta) is involved in various cellular processes and has recently been reported as an essential mediator of breast cancer development [34]. Neurofibromatosis type 1 (NF-1) is a tumor suppressor gene that inhibits RAS-GTP activation, and it has recently been reported that NF-1 mutations are associated with cancer [35]. Forkhead box P3 (FOXP3) is a protein involved in the immune system response, and the expression of FOXP3 has been reported to be associated with poor prognosis in several cancers [36]. The Paired Box-5 (Pax-5) gene is a family of nuclear transcription factors [37], has been reported to be expressed in a variety of cancers, and is likely to contribute to overall tumorigenesis [38]. Although p53 is a tumor suppressor gene and plays an important role in cell death and genomic stability, mutations in the p53 gene cause cancer [39]. Signal transducer and transcription activator (STAT4) play an important role in development, proliferation, and immune defense, but overexpression can lead to several cancers [40]. TFII-I was originally a transcription factor capable of binding to two separate promoter elements, a pyrimidine-rich initiator and the recognition site (E-box) of upstream factor 1. Recently, it has been reported that it acts as an activator of other factors and affects breast and liver cancer [41]. Therefore, the presence of these
transcription factors leads to speculation that the ABL1-MS1 region may influence ABL1 activity.

In order to investigate the effect of the ABL1-MS1 region on the expression, four ABL1-promoter vectors with TRs inserted into the enhancer region was constructed. When transfected with 293 T, suppression of the luciferase activity by TR was observed, but not in bladder cancer cells. Therefore, this influence on the expression of the TR region suppresses the expression of ABL1 in non-cancer cells, but does not suppress the expression of ABL1 in cancer cells. Although we could not find a statistically significant difference based upon TRs length, we identified the potential of ABL1-MS1 in ABL1 expression regulation. We hypothesized that the ABL1-MS1 polymorphism loses its ability to suppress the expression regulation. We hypothesized that the ABL1-MS1 region may influence transcription factors leads to speculation that the ABL1 promoter region can affect ABL1-MS1 in bladder cancer is needed.

Our study used a limited number of samples to investigate the effect of repeat sequences in the ABL1-MS1 region on control and bladder cancer patients. In the future, studies on samples of various cases of bladder cancer patients are needed, and studies on how the influence of transcription factors related to the ABL1 promoter region can affect ABL1-MS1 in bladder cancer is needed.

**Conclusion**

We investigated the structural characterization of the ABL1 breakpoint region, identified one variable number of tandem repeats (VNTR) present in Intron 1 and named it ABL1-MS1. Two rare alleles (TR14, TR16) were detected in bladder cancer, and a statistically significant association was confirmed between the rare ABL1-MS1 allele and bladder cancer risk: \( P = 0.013 \). We also examined the transcription level of the reporter gene driven by the ABL1 promoter to determine if the VNTR region influenced gene expression, and that VNTR showed inhibition of ABL1 expression in non-cancer cells 293 T, but not in bladder cancer cells. In addition, it was confirmed that ABL1-MS1 is accurately transmitted to offspring according to Mendelian inheritance through meiosis. Therefore, it is suggested that the ABL1-MS1 region may affect the regulation of ABL1 expression in bladder cancer, and the identification of rare alleles of the ABL1-MS1 may suggest predictability as a susceptibility marker for bladder cancer.

**Abbreviations**

- VNTR: Variable number of tandem repeats
- ABL1: Abelson murine leukemia virus oncogene homolog 1
- RTK: Receptor tyrosine kinase
- CAMP: Cyclic AMP
- BCR: Breakpoint cluster region
- NMIBC: Non-muscle invasive bladder cancer
- MIIBC: Muscle invasive bladder cancer
- LOH: Loss of heterozygosity
- SSLP: Simple sequence length polymorphism
- MS: Minisatellite
- ORs: Odds ratios
- Cl: Confidence intervals
- SE: Standard error
- LINE: Long interspersed nuclear element
- LTR: Long terminal repeat
- GR: Glucocorticoid receptor
- EBF: Early B-cell factor
- C/EBP beta:CCAAT enhancer-binding protein beta
- NF-1: Neurofibromatosis type 1
- FOXP3: Forkhead box

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12920-021-00968-1.

**Additional file 1:** Figure S1. Analysis of repeat sequence distribution of ABL1 breakpoint cluster region. (a) Schematic diagram of repeat sequence within ABL1 breakpoint region. The black horizontal line represents the ABL1 breakpoint region and the vertical bar represents the position of the repeat sequence. All repeat sequences were analyzed through Repeatmasker and the UCSC database. (b) The diagram represents the number of different repeat sequences within the ABL1 breakpoint area. **Figure S2:** Analysis of distances between repeat units and identification of putative binding sites for transcription factors of four minisatellites in the ABL1-MS1 region. (a) Phylogenetic trees for the repeat units within each allele of ABL1-MS1. Numbers above branches represent bootstrap value (%) for the clades with 1000 replicates. (b) Composition of putative transcriptional factors on each minisatellite of the ABL1-MS1 region.

**Additional file 2:** Supplementary Table S1. Homology comparison of repeat sequences in the ABL1-MS1 region.
References

1. Wang JY. The capable ABL: What is its biological function? Mol Cell Biol. 2014;34(7):1188–97.
2. Kang ZJ, Liu YF, Xu LJ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:15.
3. Nandagopalan SR, Kulia N, Biswas S, Pattanayak NC, Biswas G, Chakraborty S. Dual transcripts of BCR-ABL and different polymorphisms in chronic myeloid leukemia patients. Indian J Med Res. 2016;143:36–41.
4. Jeffs AR, Wells E, Morris CM. Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions. Genes Chromosom Cancer. 2001;32(2):144–54.
5. Gil-Henn H, Patrasialo A, Wang Y, Warren MS, Condeelis JS, Koleske AJ. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer cells. Cancer Res. 2006;66(11):5648–55.
6. Huang TH, Zhou FL, Wang-Johanning F, Nan KJ, Wei YC. Depression accelerates the development of gastric cancer through reactive oxygen species-activated ABL1 (Review). Oncol Rep. 2016;36(5):2435–43.
7. Srinivasan D, Plattert R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res. 2006;66(1):5648–55.
8. Srinivasan D, Sims JT, Plattert R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2008;27(8):1095–105.
9. Boegemann M, Krabbe LM. Prognostic implications of immunohistochemical biomarkers in non-muscle-invasive blad cancer and muscle-invasive bladder cancer. Mini-Rev Med Chem. 2020;20(12):1133–52.
10. Kirkali Z, Chan T, Manocharan M, Alagba F, Busch C, Cheng L, Kiemelney L, Kriegmair M, Montironi R, Murphy WM, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6A):4–34.
11. Alsdousi S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Curr-Urol. 2010;2(1):56–64.
12. Qiao BL, Kerr M, Grosell B, Teo MTW, Knowles MA, Bristow RG, Phillips RM, Kiltie AE. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res. 2013;73(5):1611–20.
13. Andre F, Arnedos M, Baras AS, Belog Z, Bedard PL, Berger MF, Bierkens JS, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2014;34(7):1188–97.
14. Simoneau M, Larue H, Aboulkiss TO, Meyer F, Moore L, Fradet JL. Loss of heterozygosity detected in a short tandem repeat (STR) locus commonly used for human DNA identification. J Forensic Sci. 2000;45(5):1087–9.
15. Gneurol M, Vincenc MD, Legende M, Verstappen KJ. Varient tandem repeats accelerate evolution of coding and regulatory sequences. In: Campbell A, Lichten M, Schupbach G, editors. Annual review of genetics, vol. 44. Palo Alto: Annual Reviews, 2010. p. 445–77.
16. Sonay TB, Carvalho T, Robinson MD, Greninger PK, Krutzen M, Comas D, Highnam G, Mittelman D, Sharp A, Marques-Bonet T, et al. Tandem repeat variation in human and great ape populations and its impact on gene expression divergence. Genome Res. 2015;25(11):1591–9.
transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer. 2011;104(8):1349–55.
42. Bushweller JH. Targeting transcription factors in cancer—from undruggable to reality. Nat Rev Cancer. 2019;19(11):611–24.
43. Krumholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttrop M, Metzler M. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosom Cancer. 2012;51(11):1045–53.
44. Shibata Y, Malhotra A, Dutta A. Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET. Genome Med. 2010;2:13.
45. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000;95(3):738–44.
46. Kolomietz E, Marrano P, Yee K, Thai B, Braude I, Kolomietz A, Chun K, Minkin S, Kamel-Reid S, Minden M, et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia. 2003;17(7):1313–23.
47. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619–30.
48. Burmeister T, Groger D, Kuhn A, Hoelzer D, Thiel E, Reinhardt R. Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias. DNA Repair. 2011;10(11):1131–7.
49. Doss CGP, Sudandiradoss C, Rajasekaran R, Purohit R, Ramanathan K, Sethumadhavan R. Identification and structural comparison of deleterious mutations in nsSNPs of ABL1 gene in chronic myeloid leukemia: a bioinformatics study. J Biomed Inform. 2008;41(4):607–12.
50. Linhartova J, Hovorkova L, Soverini S, Benesova A, Jaruskova M, Klamova H, Zuna J, Polakova KM. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Mol Cancer. 2015;14:9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.